Stay updated with breaking news from Michael reth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. ....
Findings can inform vaccines, treatments for COVID, cancers, and beyond miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane. view more Credit: Illustration: Julia Jullesova Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface changes. The resting B cell is activated in the process. The team has published the research in the journal ....